One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Left Atrial Appendage Devices (LAA) Market

[ 英語タイトル ] Left Atrial Appendage Devices (LAA) Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089366
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 117
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott
- Articure
- Boston Scientific
- Johnson & Johnson
- Lifetech Scientific
- St Jude Medical
- Sentreheart Inc.

[Report Description]

The left atrial appendage devices (LAA) market is expected to register a 20 % of CAGR over the forecast period. The key contributors in the market growth are rising geriatric population and associated cardiovascular diseases. People aged 65 years and above are at a higher threat of causing cardiovascular diseases such as atrial fibrilliation which might further lead to heart stroke. According to the report “World Ageing Population”, in 2019, around 702.9 million people all around the world were aged 65 years and above. Thus, it is expected to create a healthy demand for these devices during the forecast period.

Key Market Trends

Hospital Segment is Expected to be Dominant in the Left Atrial Appendage Devices (LAA) Market

Hospital segment of the Left Atrial Appendage Devices market is expected to show a significant growth. The increasing number of hospitals and advancing infrastructure is expected to drive the demand for the devices. According to the Centres for Medicare and Medicaid Services, in 2018 around 3.6 trillion USD was spent by the United States in the health-care management. This is expected to augment the left atrial appendage devices market growth.

Furthermore, the growing burden of atrial fibrillation is expected to be a major contributor in this segment. According to the European Society of Cardiology, atrial fibrillation is one of the most common heart disorder. In 2016, the prevalence of atrial fibrillation in people aged 65 years and above was around 7.6 million and it is expected to increase by 89%, i.e., around 14 million in 2060. Hence, the aforementioned factors are expected to increase the hospital visits for left atrial appendage management and thereby increase the demand for left atrial appendage devices in this segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region in the Left Atrial Appendage Devices (LAA) market owing to the growing number of cases of atrial fibrillation. According to the Centre for Disease Control and Prevention, in 2017, between 2.7 million and 6.1 million people in the United States were living with atrial fibrillation and it is expected to increase with the growing geriatric population. Atrial Fibrillation is likely to cause heart stroke and hence, left atrial appendage management is of utmost importance. Furthermore, novel technologies are being introduced in the market which is rising the adoption of these devices. For instance, in 2018, ArtiCure, Inc. designed AtriClip FLEX•V Left Atrial Appendage (LAA) Exclusion System in the United States that enables a clip deployment trigger release. Therefore, these factors are expected to drive the market growth over the forecast period.

Competitive Landscape

Companies are taking initiatives to grow their presence in the market. In 2019, Boston Scientific Inc., received a CE mark for WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device in Europe. Key players that are expected to be dominant in Left Atrial Appendage Devices (LAA) market are Abbott, Articure, Boston Scientific, Johnson & Johnson, Lifetech Scientific, St Jude Medical and Sentreheart Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Atrial Fibrillation
4.2.2 Technological Advancements in the Devices
4.3 Market Restraints
4.3.1 High Cost of Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Endocardial
5.1.2 Epicardial
5.2 By End User
5.2.1 Hospitals
5.2.2 Ambulatory Surgical Centres
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Rest of the World

6.1 Company Profiles
6.1.1 Abbott
6.1.2 Articure
6.1.3 Boston Scientific
6.1.4 Johnson & Johnson
6.1.5 Lifetech Scientific
6.1.6 St Jude Medical
6.1.7 Sentreheart Inc.




Recommended reports